Jenburkt Pharmaceuticals Ltd has filed its quarterly compliance certificate with BSE Ltd, confirming adherence to regulatory requirements for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation as part of its ongoing compliance with SEBI regulations governing depositories and participants.

Regulatory Compliance Certificate

The company filed its certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, on April 7, 2026. The submission was made through a formal communication bearing reference number JPL/CS/2289/2026.

Registrar Confirmation

Bigshare Services Pvt. Ltd., serving as the company's Registrar and Transfer Agent, issued the compliance certificate on April 6, 2026. The registrar confirmed that securities received from depository participants for dematerialization up to March 31, 2026, were properly processed and confirmed to the depositories.

The certificate validates that all security certificates received for dematerialization have been mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as registered owners within the stipulated 15-day period of receipt of certificate of securities.

Compliance Framework

The filing demonstrates Jenburkt Pharmaceuticals' commitment to maintaining regulatory compliance with SEBI's framework for depositories and participants. The quarterly certification process ensures transparency in the dematerialization process and proper handling of securities transactions.

The submission was digitally signed by Ashish R. Shah, Vice President & Company Secretary and Compliance Officer, on April 7, 2026, at 12:01:12 +05'30', ensuring the authenticity and timeliness of the regulatory filing.

Jenburkt Pharmaceuticals Limited announced its standalone unaudited financial results for the quarter and nine months ended December 31, 2025. The pharmaceutical company's Board of Directors approved the results on February 3, 2026, following recommendations from the Audit Committee.

Financial Performance Overview

The company's financial performance for the third quarter of FY26 showed mixed results compared to the previous year. Revenue from operations declined sequentially but demonstrated year-over-year growth, while profitability faced some pressure during the quarter.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Jenburkt Pharmaceuticals demonstrated solid year-over-year growth across key financial metrics. The company's revenue expansion was supported by improved operational efficiency and market performance.

Expense Analysis

Total expenses for Q3FY26 increased to Rs 3654.22 lacs from Rs 2896.15 lacs in the corresponding quarter of the previous year. The significant expense components included employee benefit expenses of Rs 1471.36 lacs, other expenses of Rs 1209.17 lacs, and purchase of stock-in-trade of Rs 782.71 lacs. The company benefited from a positive change in inventories of Rs 150.93 lacs during the quarter.

Other Comprehensive Income

The company reported total comprehensive income of Rs 652.35 lacs for Q3FY26 compared to Rs 593.16 lacs in Q3FY25. For the nine-month period, total comprehensive income reached Rs 2557.17 lacs against Rs 2550.40 lacs in the previous year.

Corporate Governance

The financial results were reviewed and recommended by the Audit Committee before approval by the Board of Directors. The company noted that it made additional provisions in employee benefit expenses in compliance with the new Labour Codes on Wages 2019. As Jenburkt Pharmaceuticals deals exclusively in the pharmaceuticals business segment, segment-wise reporting is not applicable.

The paid-up equity share capital remained unchanged at Rs 441.33 lacs with a face value of Rs 10 per share. The Board meeting was conducted from 2:30 p.m. to 5:00 p.m. on February 3, 2026.

Source: